Skip to content
Screener

Myriad Genetics MYGN Free cash flow margin

Free cash flow margin at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
8.1%-1.3pp
Quest Diagnostics logo
Quest DiagnosticsDGX
11.7%0.0pp
NeoGenomics logo
NeoGenomicsNEO
-4.9%—
Veracyte logo
VeracyteVCYT
28.7%+11.7pp
Sera Prognostics logo
Sera PrognosticsSERA
-48,377.2%-673,104pp
Guardant Health logo
Guardant HealthGH
-22%-6.7pp

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36—

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$311.82M-46.0%
Enterprise value$397.32M-38.7%
P/S0.4×-0.3×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Calculated from Myriad Genetics’s reported figures.

free cash flow/total revenue=-17%

Based on trailing twelve months.

The source filing: Myriad Genetics’s 10-Q, filed August 7, 2024. Open the filing →

Filed
Aug 7, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q2 2024
Accession
0000899923-24-000041

FAQ

What is Myriad Genetics's free cash flow margin?
Myriad Genetics (MYGN) reported free cash flow margin of -17% in Q2 2023.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Ask your AI about Myriad Genetics's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude